Cogent Biosciences, Inc.
$37
▼
-0.09%
2026-04-21 06:09:01
www.cogentbio.com
NMS: COGT
Explore Cogent Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.05 B
Current Price
$37
52W High / Low
$43.73 / $4.12
Stock P/E
—
Book Value
$3.4
Dividend Yield
—
ROCE
-38.16%
ROE
-73.7%
Face Value
—
EPS
$-2.16
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
258
Beta
0.47
Debt / Equity
37.52
Current Ratio
14.23
Quick Ratio
14.23
Forward P/E
-52.81
Price / Sales
—
Enterprise Value
$5.28 B
EV / EBITDA
-15.98
EV / Revenue
—
Rating
Strong Buy
Target Price
$54.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Rani Therapeutics Holdings, Inc. | $0.97 | — | $118.3 M | — | -83.37% | -1.82% | $3.87 / $0.39 | $0.34 |
| 2. | VivoSim Labs, Inc. | $1.54 | — | $4.02 M | — | -115.61% | -51.07% | $5.3 / $1.25 | $1.7 |
| 3. | Actuate Therapeutics, Inc. Common stock | $2.62 | — | $54.77 M | — | -270.08% | -5.54% | $11.99 / $1.58 | $0.34 |
| 4. | Catalyst Pharmaceuticals, Inc. | $26.07 | 14.85 | $3.18 B | — | 26.94% | 25.49% | $26.58 / $19.05 | $7.79 |
| 5. | Precigen, Inc. | $4.11 | — | $1.45 B | — | -90.19% | -5.72% | $5.46 / $1.23 | $0.06 |
| 6. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
| 7. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -99.49 M | -83.36 M | -75.58 M | -74.93 M | -73.73 M | — |
| Net Profit | -102.49 M | -80.93 M | -73.53 M | -71.99 M | -67.93 M | — |
| EPS in Rs | -0.63 | -0.5 | -0.45 | -0.44 | -0.42 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -333.36 M | -275.94 M | -208.13 M | -147.84 M |
| Net Profit | -328.94 M | -255.86 M | -192.41 M | -140.24 M |
| EPS in Rs | -2.03 | -1.58 | -1.19 | -0.86 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 937.61 M | 327.9 M | 313.44 M | 300.81 M |
| Total Liabilities | 301.24 M | 71.61 M | 55.63 M | 45.08 M |
| Equity | 636.37 M | 256.29 M | 257.8 M | 255.74 M |
| Current Assets | 910.36 M | 296.47 M | 270.77 M | 264.97 M |
| Current Liabilities | 63.95 M | 55.71 M | 38.17 M | 26.85 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -264.44 M | -207.79 M | -153.62 M | -118.64 M |
| Investing CF | -399.53 M | 38.28 M | -97.82 M | -124.72 M |
| Financing CF | 878.23 M | 214.45 M | 163.54 M | 163.56 M |
| Free CF | -266 M | -208.36 M | -156.42 M | -125.5 M |
| Capex | -1.55 M | -0.57 M | -2.8 M | -6.86 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -32.98% | -37.2% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.